Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

Unusual Whales

Mar 9, 2026 at 11:32 AM

The company announced a clinical clearance rate of 73% in the cohort receiving 200 µg at Day 57.

Source: Unusual Whales The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Related Stocks

Medicus Pharma

USMDCX

+0.88%

MEDICUS PHARMA LTD C/WTS 15/11/2029(TO PUR COM)

USMDCXW

-6.03%

LongbridgeAI